Comparison of low-dose thalidomide and prednisone combined with or without danazol for the treatment of primary myelofibrosis-associated anemia

• Published in: Zhōnghuá xuèyèxué zázhì Vol. 35; no. 8; p. 698
• Main Authors: Xu, Junqing, Xu, Zefeng, Qin, Tiejun, Li, Bing, Fang, Liwei, Zhang, Hongli, Hu, Naibo, Pan, Lijuan, Qu, Shiqiang, Zhang, Yue, Xiao, Zhijian
• Format: Journal Article
• Language: Chinese
• Published: China 01.08.2014
• Subjects: Adult; Aged; Anemia - drug therapy; Anemia - etiology; Danazol - therapeutic use; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Male; Middle Aged; Prednisone - therapeutic use; Primary Myelofibrosis - complications; Retrospective Studies; Thalidomide - therapeutic use; Treatment Outcome; Young Adult
• ISSN: 0253-2727
• DOI: 10.3760/cma.j.issn.0253-2727.2014.08.006

To observe the clinical effects of low-dose thalidomide (THAL) and prednisone (PRED) with or without danazol (DANA) in patients with primary myelofibrosis (PMF) associated anemia. A cohort of 58 PMF patients with anemia (Hb<100 g/L) were retrospectively studied. Of them, 28 patients were treated with THAL and PRED (THAL-PRED group), and the rest with THAL, PRED and DANA (THAL-PRED-DANA group). The hematological response was assessed according to the modified criteria of the International Working Group in 2006, and the myelofibrosis degree was evaluated at 3 and 12 month after treatment. The total response rate was 56.9%(33/58) including 1.7% (1/58) partial remission (PR) and 55.2% (32/58) clinical improvement (CI). There was no statistical difference in the response rate between THAL-PRED and THAL-PREDDANA groups (50.0% vs 63.3%, P=0.306). However, the median response duration of clinical improvement, erythroid response (CI-E) and total response prolonged in THAL-PRED-DANA than THALPRED group (61.5w vs 22w, P